In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Rubio, C
  • Bellver, J
  • Rodrigo, L
  • Castillon, G
  • Guillen, A
  • Vidal, C
  • Giles, J
  • Ferrando, M
  • Cabanillas, S
  • Remohi, J
  • Simon, C

Grupos

Abstract

Objective: To determine the clinical value of preimplantation genetic diagnosis for aneuploidy screening (PGD-A) in women of advanced maternal age (AMA; between 38 and 41 years). Design: This was a multicenter, randomized trial with two arms: a PGD-A group with blastocyst transfer, and a control group with blastocyst transfer without PGD-A. Setting: Private reproductive centers. Patient(s): A total of 326 recruited patients fit the inclusion criteria, and 205 completed the study (100 in the PGD-A group and 105 in the control group). Intervention(s): Day-3 embryo biopsy, array comparative genomic hybridization, blastocyst transfer, and vitrification. Main Outcome Measure(s): Primary outcomes were delivery and live birth rates in the first transfer and cumulative outcome rates. Result(s): The PGD-A group exhibited significantly fewer ETs (68.0% vs. 90.5% for control) and lower miscarriage rates (2.7% vs. 39.0% for control). Delivery rate after the first transfer attempt was significantly higher in the PGD-A group per transfer (52.9% vs 24.2%) and per patient (36.0% vs. 21.9%). No significant differences were observed in the cumulative delivery rates per patient 6 months after closing the study. However, the mean number of ETs needed per live birth was lower in the PGD-A group compared with the control group (1.8 vs. 3.7), as was the time to pregnancy (7.7 vs. 14.9 weeks). Conclusion(s): Preimplantation genetic diagnosis for aneuploidy screening is superior compared with controls not only in clinical outcome at the first ET but also in dramatically decreasing miscarriage rates and shortening the time to pregnancy. (C) 2017 by American Society for Reproductive Medicine.

Datos de la publicación

ISSN/ISSNe:
0015-0282, 1556-5653

FERTILITY AND STERILITY  ELSEVIER SCIENCE INC

Tipo:
Article
Páginas:
1122-1129
Factor de Impacto:
2,250 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 76

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Aneuploidy; array-CGH; embryo biopsy; maternal age; PGD-A

Campos de estudio

Proyectos asociados

ESTUDIO DE LA ENFERMEDAD METASTASICA EN EL TEJIDO OVARICO CRIOPRESERVADO DE MUJERES CON CANCER DE MAMA

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

PI08/90483 . INSTITUTO DE SALUD CARLOS III . 2009

CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORRELL

CD11/00292 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2012

CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORELL

CD12/00568 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

CONTRATO POST FSE (RIO HORTEGA)

CM13/00191 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014

CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORRELL

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

CD15/00058 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2016

TRAMIENTO COMBINADO DE VITAMINA D CON AGNRH SOBRE EL CRECIMIENTO DE LOS MIOMAS UTERINOS

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

PI15/00312 . INSTITUTO DE SALUD CARLOS III . 2016

ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, PARA EVALUAR SEGURIDAD Y EFICACIA DE ELAGOLIX EN PARTICIPANTES CON DOLOR MODERADO O SEVERO ASOCIADO A ENDOMETRIOSIS.

Investigador Principal: VICENTE PAYÁ AMATE

M12-671

Cita

Compartir